Citi analyst Yigal Nochomovitz raised the firm’s price target on Apellis (APLS) to $46 from $41 and keeps a Buy rating on the shares after Empaveli received FDA label expansion approval to be the first treatment for C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis in patients over 12 years old. Citi believes Empaveli’s “best-in-class” profile should bring momentum back to the Apellis story.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APLS:
- Apellis Pharmaceuticals: Buy Rating Driven by Empaveli’s Market Potential and Strong Growth Prospects
- Apellis Pharmaceuticals Receives Buy Rating Following Empaveli’s FDA Approval and Market Potential
- FDA approves Apellis’ Empaveli for treatment of C3 glomerulopathy
- Apellis Pharmaceuticals trading halted, news pending
- Apellis price target raised to $50 from $47 at Baird